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The TPBG (trophoblast glycoprotein, HGNC:12004) is a heavily N-glycosylated transmembrane protein belong-
ing to the leucine-rich repeat family of proteins. It is typically 
expressed during fetal development and cancer.1 In murine 
embryonic stem cells and fibroblasts, and cancerous cells, 
TPBG upregulation has been associated with the induction of 
the CXCL12 (chemokine [C-X-C motif] ligand-12). In addi-
tion, TPBG prolongs CXCL12 bioavailability via the inhibi-
tion of DPP4 (dipeptidyl peptidase-4), a protease responsible 
for CXCL12 cleavage.1–3 Mechanistically, the TPBG/CXCL12 
duo exert a modulatory control of gene transcription, prolifera-
tion, and directional movement of cancerous cells.1,4–6 CXCL12 
triggers intracellular signaling by binding to CXCR4 (C-X-C 
chemokine receptor-4) as well as to the noncanonical CXCR7 
(C-X-C chemokine receptor-7) and CXCR4/CXCR7 heterodi-
mers. The activated CXCR4 induces intracellular G-coupled 
protein cell signaling and is degraded after CXCL12-elicited 
internalization.6 In contrast, CXCR7 becomes dominant after 
TPBG downregulation, signals through G-coupled protein in-
dependent mechanisms, and functions, at least, in part, as a 
chemokine decoy receptor for CXCL12.3,7–11 Interestingly, 
both CXCR4 and CXCR7 can also form complexes with 
β-arrestin-2, thereby promoting receptor internalization and 
redirecting signaling to alternative G protein-independent 
pathways. For instance, β-arrestin-2 is reportedly involved in 
CXCR4- and CXCR7-mediated chemotaxis, and this is medi-
ated by p38 MAPK/ERK (p38 mitogen-activated protein ki-
nase/extracellular signal–regulated kinases) activation.12,13
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Objective—To determine the role of the oncofetal protein TPBG (trophoblast glycoprotein) in normal vascular function and 
reparative vascularization.
Approach and Results—Immunohistochemistry of human veins was used to show TPBG expression in vascular smooth 
muscle cells and adventitial pericyte-like cells (APCs). ELISA, Western blot, immunocytochemistry, and proximity 
ligation assays evidenced a hypoxia-dependent upregulation of TPBG in APCs not found in vascular smooth muscle 
cells or endothelial cells. This involves the transcriptional modulator CITED2 (Atypical chemokine receptor 3 CBP/
p300-interacting transactivator with glutamic acid (E)/aspartic acid (D)-rich tail) and downstream activation of CXCL12 
(chemokine [C-X-C motif] ligand-12) signaling through the CXCR7 (C-X-C chemokine receptor type 7) receptor and 
ERK1/2 (extracellular signal-regulated kinases 1/2). TPBG silencing by siRNA transfection downregulated CXCL12, 
CXCR7, and pERK (phospho Thr202/Tyr204 ERK1/2) and reduced the APC migratory and proangiogenic capacities. 
TPBG forced expression induced opposite effects, which were associated with the formation of CXCR7/CXCR4 (C-X-C 
chemokine receptor type 4) heterodimers and could be contrasted by CXCL12 and CXCR7 neutralization. In vivo 
Matrigel plug assays using APCs with or without TPBG silencing evidenced TPBG is essential for angiogenesis. Finally, 
in immunosuppressed mice with limb ischemia, intramuscular injection of TPBG-overexpressing APCs surpassed naïve 
APCs in enhancing perfusion recovery and reducing the rate of toe necrosis.
Conclusions—TPBG orchestrates the migratory and angiogenic activities of pericytes through the activation of the CXCL12/
CXCR7/pERK axis. This novel mechanism could be a relevant target for therapeutic improvement of reparative angiogenesis.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2019;39:1113-
1124. DOI: 10.1161/ATVBAHA.119.312665.)
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TPBG is also considered an early marker of the epithe-
lial-to-mesenchymal transition (EMT) and the cognate endo-
thelial-to-mesenchymal process, along with MMPs (matrix 
metalloproteinases), the E-cadherin repressors SNAI (Snail 
Family Transcriptional Repressor) 1 and 2, and the transcrip-
tional factors ZEB (zinc finger E-box binding homeobox) 
and TWIST (twist family BHLH transcription factor) 1.14–17 
Cancerous cells undergoing EMT manifest multiple biochem-
ical changes that enable them to acquire enhanced migratory 
capacity, invasiveness, and elevated resistance to apoptosis.18 
Furthermore, recent studies showed a similar transition confers 
cancerous cells with the characteristics of pericytes, thereby 
favoring vascular remodeling, sustained tumor growth, and 
increased invasiveness.19,20 However, to the best of our know-
ledge, no data are currently available regarding a possible role 
of TPBG in postnatal vascular repair.
The present study investigates the potential role of TPBG 
in pericyte biology. In particular, we focus on a subset of peri-
cyte-like cells isolated from the adventitial vasa vasorum, oth-
erwise known as adventitial pericytes (APCs).21–23
Materials and Methods
All data and supporting materials have been provided with the pub-
lished article (The authors declare that all supporting data are avail-
able within the article [and its online supplementary files]). The 
article adheres to the American Heart Association Journals Guidelines 
Implementation of the Transparency and Openness Promotion. All 
studies performed on human tissues and cells followed the ethical 
guidelines of the Declaration of Helsinki. Animal experiments were 
performed in accordance with the Animal (Scientific Procedures) 
Act (United Kingdom) 1986 prepared by the Institute of Laboratory 
Animal Resources and under the auspices of UK Home Office Project 
and Personal License. Results are reported following the guidelines 
contained in the Animal Research Report of In Vivo Experiments.
Commercial human umbilical cord endothelial cells (HUVECs, 
Lonza) or aortic vascular smooth muscle cells (VSMCs, PromoCell) 
have been cultured according to provider’s instructions, while human 
APCs and murine CD31 or CSPG4 were immunomagnetic isolated 
from human veins or ischemic limbs, respectively, according to pre-
vious publications.21,24
Forced TPBG overexpression experiments were performed using 
adenoviral constructs. Adenoviral titration was calculated accord-
ing to previous publications.25 PcDNA3-CITED2-hemagglutinin 
was from Shoumo Bhattacharya26 used to study effect of CITED2 
(Atypical chemokine receptor 3 CBP/p300-interacting transactivator 
with glutamic acid (E)/aspartic acid (D)-rich tail) overexpression on 
TPBG. Additional ChIP assays performed as previously described27 
were used to evidence CITED2-TPBG binding.
Refer to Material in the online-only Data Supplement for further 
information.
Results
Expression of TPBG in Human 
Veins and Vascular Cells
To identify the localization of TPBG, we performed multi-
color immunohistochemistry staining of human veins. Results 
indicate TPBG is expressed by VSMCs in the tunica media 
and CD34/CSPG4 positive APCs in proximity of the adven-
titial vasa vasorum (Figure IA and IB in the online-only Data 
Supplement). Flow cytometry of culture-expanded APCs con-
firmed TPBG was expressed by >95% of the cells, together 
with pericyte and mesenchymal markers, such as CD105, 
CD90, CD44, CSPG4, and PDGFR (platelet-derived growth 
factor receptor)-β. As expected, APCs were negative for 
CD31, CD146, and CD45 (Figure IC and ID in the online-only 
Data Supplement). We next compared the TPBG transcript 
levels in APCs, HUVECs, and proliferative or contractile 
VSMCs (Figure IE in the online-only Data Supplement). In 
sequence, proliferative VSMCs showed the highest number of 
TPBG transcript copies (10 135±2066, P<0.01 versus APCs), 
followed by contractile VSMC (7003±966, P=0.85 versus 
APCs), APCs (6889±661, P<0.001 versus HUVECs), and 
HUVECs (563±292). Positive and negative controls for the 
antibody and fluorescent technique are shown in Figure IIA 
and IIB in the online-only Data Supplement.
TPBG expression has been associated with migratory/
invasive profiles in cancer cells.18 Here, we show that TPBG 
expression is influenced by changes in APC confluence, with 
sparse cells showing higher TPBG levels than confluent cells 
(Figure IIIA through IIIC in the online-only Data Supplement). 
In addition, an in vitro scratch assay showed that physical dis-
continuation of APC monolayers increased the expression of 
TPBG, with positive staining being evident in the filopodia 
at the wound edges (Figure IIID and IIIE in the online-only 
Data Supplement). To the best of our knowledge, this is the 
first demonstration of TPBG being expressed by mural cells 
in adult human blood vessels and associated with cell motility.
Hypoxia Induces TPBG Expression 
in Human APCs
We next asked whether hypoxia may induce TPBG in APCs. 
In line with this possibility, hypoxia increased TPBG tran-
script levels compared with normoxia (1.6-fold at 12 hours 
and 2.0-fold at 24 hours, P<0.05 for both comparisons). TPBG 
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mRNA returned to baseline under prolonged hypoxia condi-
tioning (Figure 1A). In contrast, neither HUVECs nor VSMCs 
(3 cell lines each) exhibited TPBG regulation after hypoxic 
conditioning (data not shown). We verified that immunoreac-
tive TPBG protein is modulated by hypoxia in APC lysates 
(P<0.01 versus normoxia) and cell conditioned media (CCM; 
P<0.05 versus normoxia) using ELISA assays (Figure 1B). 
The TPBG content in the secretome was further assessed by 
Western blotting, using a different anti-TPBG antibody to 
verify the ELISA results (Figure 1C). Proximity ligation assay 
(PLA) was used for target validation and antibody specificity 
(Figure IV in the online-only Data Supplement), also confirm-
ing the modulation of TPBG by hypoxia (Figure IVA and IVD 
in the online-only Data Supplement).
As stated above, TPBG is considered an EMT marker. 
Accordingly, the modulation of TPBG by hypoxia was as-
sociated with a concordant induction of the EMT transcrip-
tion factors TWIST, SNAI1, SNAI2, and ZEB2 (P<0.05 versus 
normoxia for all comparisons; Figure VA through VD in 
the online-only Data Supplement). In contrast, the levels of 
TIMP1 and TIMP2 were temporarily decreased (P<0.05 and 
P<0.01 after 24 hours of hypoxia; Figure VE and VF in the 
online-only Data Supplement). MMPs followed discordant 
patterns, with MMP2 transcripts and gelatinolytic activity 
being increased (P<0.05 versus normoxia; Figure VG and VH 
in the online-only Data Supplement), and MMP9 transcripts 
remaining unchanged (data not shown). To verify the depend-
ency of the above EMT markers on TPBG, we measured their 
expression following TPBG silencing by siRNA. Results in-
dicate SNAI2, TIMP1, and TIMP2 were all suppressed by the 
TPBG inhibition in normoxic or hypoxic APCs (Figure VI and 
VN in the online-only Data Supplement).
Hypoxia Induces the CXCL12/CXCR7 Axis in  
Human APCs
Previous investigation has shown that TPBG is required for 
CXCL12-mediated chemotaxis via ligand interaction with either 
CXCR4 or CXCR7 receptors in embryo fibroblasts and can-
cerous cells.1,3 Interestingly, we found that hypoxic-dependent 
induction of TPBG was associated with an increased expression 
and secretion of CXCL12 by human APCs (P<0.05 versus nor-
moxia; Figure 2A and 2B). No significant changes were found 
about other cytokines implicated in chemotaxis (such as CCL2/
MCP1, CXCL2/GRO β [C-X-C motif chemokine 2/growth-
regulated protein beta], and CXCL1/GRO-α [C-X-C motif che-
mokine 1/growth-regulated alpha protein]; data not shown).28,29
In addition, immunocytochemistry (ICC) and PLA tech-
niques showed a differential pattern of expression and sub-
cellular localization for CXCR4 and CXCR7 receptors 
(Figure 2C and 2D). In normoxic APCs, CXCR4 prevailed 
over CXCR7, whereas following hypoxia CXCR4 acquired 
a prevalent nuclear localization and CXCR7 became upreg-
ulated. The latter result was confirmed by measurement of 
CXCR7 mRNA levels, which showed a 4.2-fold increase 
versus normoxia (P<0.01; data not shown). Similar changes 
in the repertoire and subcellular localization of CXCL12 
receptors has been associated with the migratory phenotype 
of metastatic cells.1,30 But never reported previously in vas-
cular pericytes. The PLA experiment illustrated in Figure 2D 
shows additional features of molecular changes induced by 
Figure 1. Hypoxia induces TPBG expression in human adventitial pericytes (APCs). A, Hypoxic-dependent modulation of TPBG (trophoblast glycoprotein) 
in 3 APC lines. Data are fold changes (mean±SEM) at the corresponding normoxia time points. Unpaired t tests were used to compare hypoxia vs normoxia; 
*P<0.05. B, TPBG levels were assessed by ELISA in lysates and conditioned media (CCM) of the same APC lines. Data are fold changes (mean±SEM) vs cor-
responding normoxia time points. Not assessed (na). Unpaired t tests were used to compare hypoxia vs normoxia; *P<0.05 and **P<0.01. C, Representative 
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hypoxia: first, it confirmed at the molecular level that hypoxia 
induced the candidate target TPBG (upper); second, it verified 
the concomitant upregulation of CXCR7 (lower); and third, 
using antibodies against CXCR4 and CXCR7, it demonstrated 
that hypoxia caused the formation of receptor heterodimers 
(middle). In contrast, no PLA signals were detected when only 
one primary antibody was used or when both primary antibod-
ies were omitted (data not shown).
We also measured the expression of DPP4, one pivotal 
CXCL12 degrading protease, and found it to be downregu-
lated at the transcript and protein level after 72 hours of hy-
poxia (0.68±0.11 DPP4 mRNA fold change versus normoxia, 
P<0.05; 0.53±0.09 DPP4 secreted fold change, P<0.001 
versus normoxia). Altogether, these data indicate hypoxia has 
a profound impact on different components of the CXCL12 
pathway, which would be expected to result in the activation 
of downstream kinase signaling. In line with this, we found 
that hypoxic conditioning of APCs induces the phosphoryla-
tion of ERK (Figure 2E and 2F), which is a typical target of 
CXCL12 binding to CXCR7.6
Forced Modulation of TPBG Expression 
Alters APC Functional Behavior Through the 
CXCL12/CXCR7/pERK Signaling Pathway
The functional implications of the TPBG/CXCL12 partner-
ship were further investigated by silencing or overexpressing 
TPBG in human APCs under normoxia or hypoxia.
In silencing experiments, normoxic or hypoxic APCs were 
transfected with TPBG siRNAs (siTPBG) or scramble con-
trols (siCtrl). The latter did not alter the inductive effect of hy-
poxia on TPBG, CXCL12, and CXCR7 expression (Figure 3A 
through 3D). siTPBG efficiently reduced the transcript and 
protein levels of TPBG in normoxic or hypoxic APCs, as dem-
onstrated by quantitative polymerase chain reaction (qPCR), 
Western blot, and PLA (Figure 3A and 2B, P<0.01 versus siC-
trl; Figure IVB and IVD in the online-only Data Supplement).
Next, we investigated whether TPBG silencing would 
affect the APC behavior. Previous studies have attributed 
TPBG with the properties of an early differentiation marker in 
mouse embryonic stem cells, and its absence may be a useful 
mean to assess pluripotency.14 APCs coexpress typical peri-
cyte/stromal cell markers together with stemness antigens.21 
Therefore, we verified the effect of siTPBG on the APC an-
tigenic profile and found no change as compared with siCtrl-
treated APCs (data not shown). Similarly, siTPBG did not 
cause any effect on proliferation or apoptosis (data not shown). 
Looking at CXCL12 expression and CXCL12-associated 
functions, we found that, in normoxic APCs, siTPBG reduced 
CXCL12 (Figure 3E and 3F), CXCR7 (Figure 3G and 3H), 
and pERK (Thr202/Tyr204; Figure 3I and 3J), with these 
effects being associated with diminished migratory activity in 
a scratch assay (0.66±0.03 gap closure fold change, P<0.01 
versus siCtrl) and impaired capacity to support endothelial 
Figure 2. Hypoxic-dependent regulation of the CXCL12 (chemokine 
[C-X-C motif] ligand-12) signaling in human adventitial pericytes (APCs). 
A–D, The modulation of the CXCL12/CXCR4 (C-X-C chemokine receptor 
type 4)/CXCR7 (C-X-C chemokine receptor type 7) axis by hypoxia was 
studied in 4 to 5 APC lines. Hypoxia increases the levels of CXCL12 at 
mRNA (A) and immunoreactive protein level (B). Data are fold changes 
(mean±SEM) vs corresponding normoxia time points. Unpaired t tests 
were used to compare hypoxia vs normoxia in 5 APC lines, *P<0.05. Rep-
resentative images of immunohistochemistry (C) and proximity ligation 
assay (PLA; D) from studies performed in 4 APC (Continued )
Figure 2 Continued. lines to verify the expression and subcellular locali-
zation of TPBG (trophoblast glycoprotein), CXCR4, and CXCR7. E and F, 
Hypoxia induces the phosphorylation of ERK (Thr202/Tyr204; extracellular 
signal-regulated kinases 1/2). Representative Western blot images (E) and 
results of densitometry (F). Data are fold changes (mean±SEM) vs corre-
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network formation on Matrigel (0.65±0.07 tube length fold 
change, P<0.01 versus siCtrl; Figure 3K through 3N). In hy-
poxic APCs, siTPBG was once again associated with low-
ered levels of the CXCL12, CXCR7, and pERK (Figure 3O 
through 3T) and diminished migratory activity (Figure 3U 
and 3V). No effect of silencing was observed on other che-
mokines, such as CCL2/MCP1, CXCL2/GRO, and CXCL1, 
or DPP4 in normoxic or hypoxic conditions (data not shown).
We next assessed the impact of transfecting APCs with 
Ad-TPBG; the empty backbone Ad-Null was used as a con-
trol (Figure 4). These experiments were performed under nor-
moxic conditions to verify if forced TPBG expression could 
phenocopy the effects observed under hypoxia. Effective 
transduction was evidenced by qPCR, Western blot, PLA, 
and ICC (Figure 4A and 4B; Figures IVC and IVD and VI in 
the online-only Data Supplement). In addition, we found that 
TPBG-transduced APCs retained the capacity to upregulate 
the endogenous protein following exposure to hypoxia (Figure 
VID in the online-only Data Supplement).
Forced TPBG expression was associated with increased 
CXCL12 secretion into the culture media (1.38±0.01-fold, 
P<0.001 versus Ad-Null; Figure 4C). Looking at the CXCL12 
receptors, we could not observe any effect of Ad-TPBG on 
the expression levels and subcellular localization of CXCR4 
and CXCR7, as assessed by ICC (Figure 4D, upper). 
Therefore, the nuclear import of CXCR4 and upregulation 
of CXCR7 seem to be a unique prerogative of APCs exposed 
to hypoxia. On the contrary, PLA demonstrated that TPBG-
transduced APCs carry CXCR7/CXCR4 heterodimers as 
also seen in hypoxic APCs (Figure 4D, lower). In the scratch 
assay, TPBG-transduced APCs showed a 5.4-fold increase in 
gap closure compared with Ad-Null treated APCs (P<0.01, 
Figure 4E and 4F). Finally, we examined the effect of forced 
TPBG expression on the APCs’ interaction with HUVECs in 
a Matrigel assay. The CCM from TPBG-transduced APCs did 
not promote any increase in network formation as compared 
with the CCM from Null-transfected APCs (0.94±0.02-fold 
change; data not shown). Likewise, TPBG-transduced APCs 
in coculture with HUVECs caused a modest increase in 
the length of the networks, which did not reach the statis-
tical significance (1.16±0.11-fold change versus Ad-Null, 
P=0.28; data not shown). In contrast, TPBG-transduced 
APCs could increase the HUVEC network formation when 
the 48 hours CCM from the same TPBG-transduced APCs 
was added to the coculture (1.34±0.07-fold change, P<0.01 
versus Ad-Null; Figure 4G and 4H). This latter data suggest 
cumulative effects of APCs and their CCM are responsible 
for the increased in vitro angiogenic improvement.
Figure 3. TPBG silencing inhibits CXCL12 (chemokine [C-X-C motif] ligand-12) signaling and impairs migration and network forming activity. A and B, The 
effective silencing of TPBG by siRNA was demonstrated by quantitative polymerase chain reaction (qPCR; A) and Western blot (B) in 3 adventitial pericytes 
(APC) lines under normoxic or hypoxic conditions. C and D, Bar graphs showing that hypoxia-induced upregulation of CXCL12 and CXCR7 (C-X-C chemo-
kine receptor type 7) was not altered in control APCs treated with siRNA control (siCtrl). E–J, TPBG silencing in normoxic APCs (4 cell lines) reduced the 
levels of CXCL12 mRNA (E) and secreted CXCL12 protein (F) as well as CXCR7 mRNA (G), CXCR7 protein (H), and pERK (I and J). K and L, In a scratch 
assay on 3 APC lines, TPBG (trophoblast glycoprotein) silencing impaired gap closure. M and N, In a Matrigel assay using 5 APC lines, siRNA TPBG (siTPBG) 
reduced the cell’s ability to support an endothelial network. Scale bars, 500 μm. O–V, TPBG silencing in hypoxic APCs (4 to 5 cell lines) produced similar 
effects, reducing CXCL12 mRNA (O) and secreted CXCL12 protein (P), as well as CXCR7 mRNA (Q), CXCR7 protein (R), and pERK (S and T). In addition, 
siTPBG reduced gap closure (U and V) in 3 APC lines. Scale bars, 500 μm. Data are the mean±SEM. ANOVA was used to compare multiple groups and un-
paired t tests to compare 2 groups, *P<0.05, **P<0.01, and ***P<0.001 vs siCtrl. White bars, siCtrl in normoxia (Nox) conditions; green bars, siTPBG in Nox 
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Increased Migratory and Proangiogenic 
Activities of TPBG-Transfected APCs Require 
CXCL12 Signaling Through CXCR7
We next asked whether CXCL12 is accountable for the func-
tional effects induced by forced TPBG expression in human 
APCs. To this aim, TPBG-transduced APCs were cultured 
in EGM2 (endothelial growth medium 2) for 48 hours and 
then the CCM was collected, treated with CXCL12 inhibitor 
or isotype control for 1 hour, and finally used to condition 
APCs in scratch or Matrigel assays. CXCL12 neutralization 
resulted in an impairment of the migratory (Figure 5A and 
5B) and network promotion capabilities of TPBG-transduced 
APCs (Figure 5C and 5D). To further determine the impli-
cated receptor, TPBG-transduced APCs were exposed to a 
Figure 4. Forced TPBG expression activates the CXCL12 (chemokine [C-X-C motif] ligand-12) signaling and promotes migration and network forming ac-
tivity. Adventitial pericytes (APCs) were treated with either Null vector or a TPBG expression Ad vector under normoxic conditions. Effective transduction was 
confirmed in 3 APC lines by quantitative polymerase chain reaction (qPCR; A, Western blotting in cell conditioned medium (CCM) and cell lysate (B) after 24 
h from the transfection. Forced TPBG (trophoblast glycoprotein) expression was associated with increased secretion of CXCL12 (C) and complexing of the 
CXCR4 (C-X-C chemokine receptor type 4) receptors as seen by proximity ligation assay (PLA; D). E and F, Forced expression of TPBG enhances the migra-
tion of APCs (4 cell lines) in a scratch assay. Representative microscopy images (E) and bar graphs showing fold changes vs Null (F). G and H, Matrigel assay 
in APCs (5 cell lines) treated with either Null or TPBG Ad vector and cocultured with human umbilical cord endothelial cells (HUVECs) for assessment of net-
work formation in the presence of Null-CCM or TPBG-CCM. Representative microscopy images of the networks (G) and a bar graph showing the fold change 
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neutralizing anti-CXCR7 antibody or the CXCR4 antagonist 
AMD3100, followed by addition of their own 48 hours CCM. 
Isotype IgG or solvent controls were respectively used as con-
trols. AMD3100 had no effect on migration (0.96±0.10-fold 
change, P=NS versus control). In contrast, CXCR7 neutrali-
zation impaired migration (0.66±0.04, P<0.05 versus control; 
Figure 5E and 5F). The 2 inhibitors did not alter the expres-
sion of CXCR4 and CXCR7 as assessed using Western blots 
(Figure 5G and 5H). Interestingly, blockade of CXCR7 was 
associated with lower levels of TPBG expression (0.74±0.05 
TPBG/β-tubulin fold change, P<0.01versus Isotype IgG) and 
pERK/ERK (0.76±0.11 pERK/ERK fold change, P=0.06 
versus Isotype control; Figure 5G and 5H). The latter effect 
is compatible with the inhibition of postreceptor signaling, 
while the former one may suggest the existence of a reciprocal 
cross-talk between TPBG and CXCR7.
Mechanisms Underpinning TPBG Transcription
A search of the literature on prospective transcriptional 
regulators identified CITED2 as a potential candidate for 
TPBG regulation. Transcript and protein levels of CITED2 
were assessed at different time points following APC expo-
sure to normoxia or hypoxia. CITED2 mRNA levels showed 
a reduction after 12 and 24 hours of hypoxia (Figure VIIA 
in the online-only Data Supplement). In contrast, CITED2 
protein levels were found significantly increased at 48 hours 
(Figure 6A and 6B). We next determined TPBG mRNA lev-
els in APCs transfected with full-length pcDNA3-CITED2 or 
the empty-pcDNA3 vector as a control (Figure 6C). CITED2 
forced expression increases the levels of TPBG transcript by 
1.6-fold (P<0.001 versus empty vector; Figure 6D). We next 
performed ChIP assays to determine if CITED2 influences 
TPBG directly. CITED2 has been demonstrated to bind DNA 
via AP-2 (adaptor protein complex AP-2 subunit alpha-2).31 
Promoter prediction software indicated there were 5 poten-
tial AP-2 binding sites upstream of the TPBG transcriptional 
start site (<3000 kb) and one potential site within exon 2. 
ChIP assays confirmed the occupation of CITED2 at locations 
−1985/−1836 bp and +482/+555 bp as compared with IgG or 
no antibody controls (P<0.05; Figure 6E). Quantitative ChIP 
analysis showed a further enrichment of CITED2 at the above 
locations in APCs exposed to hypoxia (P<0.05 versus IgG; 
Figure 6F). Next, we investigated if CITED2 knocking down 
blunts TPBG expression and functional effects in hypoxia. A 
pool of 4 siRNA control (siCtrl) or siRNA CITED2 was trans-
fected at 70 nmol/L. Knocking down was confirmed at the 
mRNA level by qPCR throughout the experimental follow-up 
(P<0.001 versus siCtrl; Figure 6G). ICC was used to confirm 
the location of CITED2 within the nucleus (Figure VIIB in the 
online-only Data Supplement). A reduction of immunoposi-
tive CITED2 was evidenced. Moreover, TPBG was signifi-
cantly downregulated (as seen by Western blot; Figure 6H and 
6I). TPBG downregulation was reported after 48 to 72 hours 
by an overall 0.78±0.10-fold change, P<0.05 compared with 
the siCtrl. Scratch assays additionally showed that silencing of 
CITED2 was associated with a lower migration profile in the 
Figure 5. CXCL12 (chemokine [C-X-C motif] ligand-12) and CXCR7 (C-X-C chemokine receptor type 7) neutralization inhibits the migratory and network sup-
porting activities of TPBG-transduced adventitial pericytes (APCs). A and B, Neutralization of CXCL12 reduces the migratory activity of TPBG-APCs. Rep-
resentative images (A) and bar graphs illustrating the fold change vs IgG (B). C and D, TPBG-APCs cocultured with human umbilical cord endothelial cells 
(HUVECs) were assayed in a Matrigel assay in the presence of TPBG-cell conditioned medium (CCM) containing the CXCL12 neutralizing antibody. Repre-
sentative images of the networks (C) and a bar graph illustrating the change in tube length (D). E–H, CXCR7 blockade impairs APC migration in association 
with lower levels of TPBG (trophoblast glycoprotein) and pERK. Representative images of the scratch assay (E) and bar graphs illustrating the fold change 
vs IgG (F). G, Representative Western blot images and (H) band densitometry data normalized by β-tubulin. Experiments were performed in quadruplicate or 
quintuplicate and repeated with 3 APC lines. Scale bars =0.5 mm. All values are mean±SEM. ANOVA was used to compare multiple groups and unpaired t 
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APCs, reaching the statistical significance after 48/72 hours 
(0.70±0.05, P<0.01; Figure 6J and 6K), a time that coincides 
with TPBG downregulation.
In Vivo Matrigel Plug Angiogenesis 
Assay With TPBG-Silenced APCs
Next, we performed gene silencing studies in mice, where the 
end point was the ability of TPBG to influence angiogenesis 
in vivo. In the first study, Matrigel plugs mixed with TPBG 
siRNA or control oligonucleotides were implanted subcutane-
ously. After 21 days, explanted TPBG-silenced plugs showed 
reduced microvascular networks compared with controls 
(P<0.05; Figure 7A and 7B), thus suggesting TPBG is essen-
tial for proper vascular formation.
Upregulation of TPBG in Resident 
Pericytes From Ischemic Muscles
To translate the data from in vitro hypoxia into a model of 
ischemia, we determined the expression levels of TPBG in 
vascular cells sorted from muscles of mice that underwent 
unilateral femoral artery occlusion. As shown in Figure VIII 
in the online-only Data Supplement, Tpbg mRNA levels were 
increased in CSPG4-sorted pericytes from ischemic mus-
cles (p < 0.05 versus contralateral normoperfused muscles), 
whereas the expression of Tpbg in CD31-sorted ECs was not 
altered by ischemia. These data indicate that, as with in vitro 
hypoxia, in vivo ischemia induces the expression of Tpbg in 
murine pericytes.
Transplantation of TPBG-Transduced 
APCs in Mice With Limb Ischemia
We next determined if the forced expression of TPBG 
enhances the previously reported benefit of APC transplan-
tation.21,23,32 To this aim, we injected 100 000 human APCs, 
transduced with Ad-Null or Ad-TPBG, or vehicle intra-
muscularly in immunodeficient mice with limb ischemia 
(Figure 8A). The study protocol was a randomized treat-
ment, with 2 independent operators assessing the outcomes 
Figure 6. Transcriptional modulation of TPBG by CITED2 (Atypical chemokine receptor 3 CBP/p300-interacting transactivator with glutamic acid (E)/aspartic 
acid (D)-rich tail) in human adventitial pericytes (APCs). A and B, Hypoxic-dependent expression of CITED2 in 4 APC lines. A, Representative time course of 
CITED2 protein, with β-tubulin used as loading control. (−)=no hypoxic conditioning; (+)=hypoxic conditioning. B, Results of densitometry analysis. C and D, 
Forced CITED2 expression (C) is associated with TPBG upregulation (D). APCs were transfected with either pcDNA3-Empty or pcDNA3-CITED2 tagged with 
human influenza hemagglutinin (HA) nonapeptide. UBC was used as a reference transcript (n=5 replicates). E, Quantitative ChIP-polymerase chain reaction 
(PCR) analysis of occupancy by CITED2 at 5 potential binding sites around TPBG transcriptional start site (TSS) APCs under normoxic conditions (n=5 repli-
cates). F, Quantitative ChIP-PCR analyses of occupancy by CITED2 at −1985/−1836 bp and +482/+555 bp under hypoxic conditions, in the same cell lines. 
G–K, Knockdown of CITED2 was performed to validate a regulatory effect on TPBG (trophoblast glycoprotein). Silencing was evidenced at the transcript level by 
quantitative PCR (qPCR; G). Each time point was statistically studied independently by unpaired t test. Four biological replicates were studied in technical dupli-
cates or triplicates. All comparisons are done vs siRNA control (siCtrl). H and I, TPBG expression was diminished by siCITED2 as seen by Western blot. Repre-
sentative immunoblot is displayed (H) and bar graphs have been used to represent band densitometry data (I). J and K, CITED2 silencing significantly diminishes 
APC migration after 48 h. Representative images are displayed in (J). Bar graph of gap closure with values calculated as fold change to overcome donor hetero-
geneity (K). SiCtrl conditions per each donor and time point were used as controls for each comparison. Dotted line represents the Gap closure fold change =1 
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blind to the randomization codes. TPBG expression in APCs 
was verified before implantation by Western blotting of the 
cMyc-tag and assessment of total TPBG protein (Figure 8B 
and 8C).
More than 80% of the experimental subjects completed the 
study: 7/10 in the vehicle group, 8/10 in Ad-Null APC injected 
group, and 10/10 in the Ad-TPBG APC injected group. The 
different outcome was because mice from the vehicle- or the 
Ad-Null APC injected groups had to be humanely euthanized 
following the occurrence of toe necrosis, while none mani-
fested these signs in the Ad-TPBG APC injected group. The χ2 
analysis denoted a difference in the above outcome between 
Ad-TPBG and control groups (P<0.05). APC transplantation 
accelerated blood flow recovery (P<0.05). The improvement 
in reperfusion was enhanced by Ad-TPBG APCs (P<0.001; 
Figure 8D and 8F). Ad-TPBG APCs induced an increase in 
capillary density as compared with Ad-Null APCs (P<0.05; 
Figure 8G and 8H). We could not evidence the presence of 
APCs in the ischemic muscles at 21 days post-transplantation, 
as assessed by targeting c-Myc (data not shown).
Discussion
Pericytes offer a tantalizing cell source for cardiovascular re-
generative therapy.21–23,32,33 In this study, we provide the first 
evidence that TPBG is expressed in pericytes in situ and after 
in vitro expansion, is upregulated in response to hypoxia, and 
is essential for migration and proangiogenic activities. We ad-
ditionally identified the first TPBG transcriptional regulator 
to be described and demonstrated direct binding of CITED2 
on the TPBG promoter region, which is further enhanced by 
hypoxia and participates in the migratory activity of APCs 
(Graphic Abstract).
In the placenta, TPBG is coexpressed with CITED2 by 
trophoblast cells and plays key roles in cell adhesion, mi-
gration, and proper capillary patterning.34,35 Moreover, it has 
been demonstrated that hypoxia induces CITED2 gene ex-
pression through HIF (hypoxia-inducible factor)1α-mediated 
transcriptional induction, followed by rapid and transient 
upregulation of CITED2 protein.36–38 In turn, CITED2 over-
expression induces elevated TPBG transcripts,39 and upregu-
lates various components of the EMT-associated program, of 
which TPBG is an acknowledged member.40,41 Haejin et al 
have proposed that CITED2 might be a regulator of HIF1α-
dependent gene expression under hypoxic conditions.38 
CITED2 attenuates the activation of hypoxia-inducible genes 
by HIF1α through interference with the recruitment and in-
teraction of HIF1α with p300. In the present study, we re-
port that CITED2 associates with TPBG genomic regions at 
2 AP-2 binding sites, consequently increasing TPBG tran-
scription, and that binding affinity is enhanced by hypoxia. 
CITED2 knocking down further supports those findings and 
reveals the CITED2’s modulatory effect on APC migration, 
as assessed using a scratch assay.
This investigation in adult human vascular cells expands 
the information on CITED2 and TPBG available from de-
velopmental models. Cited2 knockout is lethal, leading to a 
range of defects including malformed outflow tract, aortic-
arch malformation, and abnormal microvessel development, 
which is thought to be a consequence of Cited2 regulation of 
Vegfa.42–44 Furthermore, Cited2 activity influences prolifera-
tion and patterning of placental capillaries, with Cited2 null 
placentas displaying a disorganized pericyte arrangement 
in the capillaries.35 Within human cardiovascular pathology, 
mutations of CITED2 and epigenetic modifications of its 
promoter region have been linked with congenital heart di-
sease.43,45,46 Tpbg knockout mice are viable, but adult animals 
show structural disorganization within the brain and exhibit 
a high frequency of hydrocephalus, requiring termination at 
early stages of the life.1 Interestingly, recent studies suggest 
that the dysfunction of cellular constituents of the blood-
brain barrier, including pericytes, may contribute in hydro-
cephalus.47 Our discovery of an association between CITED2 
and TPBG in human pericytes calls for new investigation on 
TPBG playing a pathogenic role in the above cardiovascular 
and brain defects.
We found several EMT-associated proteins, including 
TPBG, are induced in APCs under hypoxia (Figure 1; Figure 
V in the online-only Data Supplement). According to the 
emerging concept of EMT, stimulated epithelial cells may 
undergo a transformative process resulting in the acquisition 
of mesenchymal phenotypes endowed with migratory and 
proangiogenic properties. Here, we propose that, in analogy 
with EMT, hypoxia activates TPBG and associated partners 
to transform quiescent pericytes into migratory and proan-
giogenic pericytes. Furthermore, we show that CXCL12 sig-
naling is key in this transformative phenomenon. Studies in 
embryonic cells indicate the transient presentation of TPBG at 
the plasma membrane during differentiation allows CXCL12 
signal transduction through CXCR4.3 Translating the above 
scheme into our experimental setting, we found hypoxia-
induced TPBG expression was associated with a significant 
increase in CXCL12 transcription and secretion and reduction 
in DPP4 release. Hypoxia did not affect the expression of the 
canonical CXCR4 receptor but changed its subcellular loca-
tion to the nucleus. This was associated with increased levels 
of CXCR7, the formation of CXCR7/CXCR4 heterodimer 
complexes and phosphorylation of ERK. These are typical 
Figure 7. In vivo plug assay. A, Representative images showing the 
microvessels positive for CD31 (red) in the Matrigel plug. Five animals per 
group were studied. Scale bars, 50 μm. B, Quantification of the area of 
CD31 coverage in the Matrigel plugs mixed with TPBG siRNA (siTPBG) 
or control oligonucleotides at 21 d after implantation. Individual values 
and mean±SEM. Unpaired t test to compare 2 groups. DAPI indicates 
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modifications seen during acquisition of a migratory pheno-
type in cancerous cells.1
To establish the cause-effect relationship between TPBG 
and the CXCL12 migratory signaling, we performed gene ti-
tration studies using TPBG siRNA and an overexpressing vec-
tor in functional assays (Figures 3 and 4). Results of silencing 
confirm that TPBG is essential for the operativity of the 
CXCL12 migratory and angiogenic program in human APCs. 
As seen under hypoxia, forced TPBG expression induced a 
promigratory phenotype, which was associated with the for-
mation of CXCR7/CXCR4 heterodimers and ERK phospho-
rylation. All these effects could be contrasted by CXCL12 
neutralization or CXCR7 blockade. Altogether, these data 
suggest that CXCR7, which has been previously considered 
a decoy receptor, plays important functional roles in key ac-
tivities of pericytes. Moreover, the murine angiogenesis plug 
assay model further validated the role of TPBG in postnatal 
neovascularization.
Preconditioning and genetic modification of donor cells 
have been considered as a potential strategy to increase re-
sistance to ischemic stress, ultimately boosting therapeutic 
efficacy.48–50 Accordingly, our study shows that, although resi-
dent pericytes already provide an endogenous source of TPBG 
under ischemia, transplantation of TPBG-overexpressing 
APCs improved the hemodynamic recovery and reparative 
capillarization compared with spontaneous responses observed 
in control mice. A puzzling aspect of data in the Ad-Null APC 
injected group is represented by the improvement in blood 
Figure 8. TPBG-transduced adventitial pericytes (APCs) improve recovery from limb ischemia. A, Mice were randomized to 3 treatment groups (n=7–10 
each). APCs were transduced with an adenoviral construct containing c-Myc-tagged TPBG (Ad-TPBG) or an Ad-Null (moi 12) and injected in the ischemic 
adductor muscles after femoral artery ligation. A third group was injected with vehicle. Doppler imaging was performed at days 0, 7, 14, and 21. B and C, 
The overexpression of TPBG (trophoblast glycoprotein) was demonstrated by targeting the tagged sequence c-Myc (B). Representative blot showing the 
total amount of TPBG, including exogenous and endogenous (C). D–F, Representative images of laser Doppler blood flowmetry at baseline and during re-
covery (D). Graph showing the recovery pattern in the 3 study groups illustrated as nonlinear regression fits and mean±SEM for each time point (E). Bar graph 
showing slope values of recovery regression lines (F; *P<0.05 and ***P<0.001 vs vehicle; missing not at random [not ignorable] data from animals prematurely 
sacrificed because of the appearance of necrotic toes were imputed according to the worst scenario (the lowest value of the series). G and H, Immunohisto-
chemistry assessment of vascular density performed in abductor muscles harvested from the ischemic left limb. IB4 (isolectin B4; green) and α-SMA (alpha 
smooth muscle actin; red) were immunostained to identify capillaries and arterioles. All samples were counterstained with 4′,6-diamidino-2-phenylindole 
(DAPI; blue). Representative images (G) and box and whiskers graphs showing minimum and maximum values (H; #P<0.05 vs Ad-Null APCs). ANOVA was 
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flow despite no change in vascular density. A possible expla-
nation is that cell therapy produced an increase in the size of 
collaterals in proximity to the artery occlusion, which could 
not be detected by the assessment of microvascular density 
in muscles. Intriguingly, we observed TPBG-overexpressing 
APCs induce a clinical improvement in toe necrosis as com-
pared with Ad-Null APCs or vehicle, which indicate a positive 
effect on cicatrization and re-epithelialization. We speculate 
that this benefit is the result of paracrine and autocrine effects 
of upregulated CXCL12 signaling. In line with our findings, a 
recent publication has demonstrated that in situ bioengineered 
CXCL12 delivery enhances wound healing in different path-
ological scenarios including murine models of peripheral is-
chemia and hyperglycemia and wound healing of human skin 
models.51 The rationale of using a gain of function approach in 
the in vivo studies was 2-fold. First, our research on APCs has 
a translational goal with the ultimate intention to find solutions 
for the treatment of ischemic disease. Second, although recog-
nizing the mechanistic value of silencing therapeutic genes to 
obtain proof of concept, we were reluctant to use an approach 
that might be harmful to the critical limb ischemia model for 
reasons intrinsic to the guidelines of our ethical license.
In conclusion, the present study pinpoints TPBG as a novel 
mechanistic modulator of pericyte functions instrumental to 
vascular physiology and repair. Targeting TPBG may have, 
therefore, a relevant impact on regenerative therapies.
Acknowledgments
The data contained in this article were shown in a poster entitled, 
“Trophoblast Oncofoetal Glycoprotein Antigen is required for human 
pericyte migration and proangiogenesis effects” during the American 
Heart Association Scientific Sessions, 2015. We thank the research 
nurses and administrators for the patient enrollment and collection 
of samples as well as Wolfson Bioimaging Facility for its technical 
support. Dr Spencer and E. Jover contributed to experimental design 
and hypothesis elaboration, collection and assembly of data, and data 
analysis and interpretation, article writing; W. Cathery, E. Avolio, 
V.V. Alvino, M. Fagnano, C. Reni, J. Rowlinson, I. Rodriguez-
Arabaolaza, R. Vono, G. Spinetti, and A. P. Beltrami to collection 
and assembly of data; Z. Dang and A. C. Thomas to collection and 
assembly of data and in vivo experiments; G. Sala-Newby to viral 
vector design and production and scientific discussions; A. Caporali, 
C. Gargioli, and G. Angelini to provision of study material; and P. 
Madeddu to conception and design, financial support, data analysis, 
interpretation, and article writing.
Sources of Funding
This research was funded by the MRC research grant (Grant number 
MR/J015350/1), by the British Heart Foundation (BHF) (Grant 
number PG/15/95/31853), by the National Institute for Health 
Research Biomedical Research Centre at University Hospitals Bristol 
NHS Foundation Trust and the University of Bristol and by the Heart 
Research UK (HRUK) (Grant number RG2656/17/20). The Bristol 
Heart Institute is part of the BHF Centre of Excellence in Vascular 





 1. Southgate TD, McGinn OJ, Castro FV, Rutkowski AJ, Al-Muftah M, 
Marinov G, Smethurst GJ, Shaw D, Ward CM, Miller CJ, Stern PL.  
CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glyco-
protein in mouse embryonic cells. PLoS One. 2010;5:e9982. doi: 
10.1371/journal.pone.0009982
 2. Christopherson KW II, Hangoc G, Mantel CR, Broxmeyer HE. Modulation 
of hematopoietic stem cell homing and engraftment by CD26. Science. 
2004;305:1000–1003. doi: 10.1126/science.1097071
 3. McGinn OJ, Marinov G, Sawan S, Stern PL. CXCL12 receptor prefer-
ence, signal transduction, biological response and the expression of 5T4 
oncofoetal glycoprotein. J Cell Sci. 2012;125(pt 22):5467–5478. doi: 
10.1242/jcs.109488
 4. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between 
tumor cells and their microenvironment. Blood. 2006;107:1761–1767. 
doi: 10.1182/blood-2005-08-3182
 5. Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim 
Biophys Acta. 2007;1768:952–963. doi: 10.1016/j.bbamem.2006.11.002
 6. Pawig L, Klasen C, Weber C, Bernhagen J, Noels H. Diversity and inter-
connections in the CXCR4 chemokine receptor/ligand family: molecular 
perspectives. Front Immunol. 2015;6:429. doi: 10.3389/fimmu.2015.00429
 7. Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP, 
Gerard C, Lefkowitz RJ. Beta-arrestin- but not G protein-mediated signal-
ing by the “decoy” receptor CXCR7. Proc Natl Acad Sci USA. 2010;107: 
628–632.
 8. Boldajipour B, Mahabaleshwar H, Kardash E, Reichman-Fried M, 
Blaser H, Minina S, Wilson D, Xu Q, Raz E. Control of chemokine-
guided cell migration by ligand sequestration. Cell. 2008;132:463–473. 
doi: 10.1016/j.cell.2007.12.034
 9. Luker KE, Steele JM, Mihalko LA, Ray P, Luker GD. Constitutive and 
chemokine-dependent internalization and recycling of CXCR7 in breast 
cancer cells to degrade chemokine ligands. Oncogene. 2010;29:4599–
4610. doi: 10.1038/onc.2010.212
 10. Naumann U, Cameroni E, Pruenster M, Mahabaleshwar H, Raz E, Zerwes HG, 
Rot A, Thelen M. CXCR7 functions as a scavenger for CXCL12 and 
CXCL11. PLoS One. 2010;5:e9175. doi: 10.1371/journal.pone.0009175
 11. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, 
Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, 
Wright K, Howard MC, Schall TJ. A novel chemokine receptor for SDF-1 
and I-TAC involved in cell survival, cell adhesion, and tumor develop-
ment. J Exp Med. 2006;203:2201–2213. doi: 10.1084/jem.20052144
 12. Sun Y, Cheng Z, Ma L, Pei G. Beta-arrestin2 is critically involved in 
CXCR4-mediated chemotaxis, and this is mediated by its enhancement 
of p38 MAPK activation. J Biol Chem. 2002;277:49212–49219. doi: 
10.1074/jbc.M207294200
 13. Cheng ZJ, Zhao J, Sun Y, Hu W, Wu YL, Cen B, Wu GX, Pei G. beta-
arrestin differentially regulates the chemokine receptor CXCR4-
mediated signaling and receptor internalization, and this implicates 
multiple interaction sites between beta-arrestin and CXCR4. J Biol Chem. 
2000;275:2479–2485.
 14. Ward CM, Barrow K, Woods AM, Stern PL. The 5T4 oncofoetal antigen is 
an early differentiation marker of mouse ES cells and its absence is a use-
ful means to assess pluripotency. J Cell Sci. 2003;116(pt 22):4533–4542. 
doi: 10.1242/jcs.00767
 15. Spencer HL, Eastham AM, Merry CL, Southgate TD, Perez-Campo F, 
Soncin F, Ritson S, Kemler R, Stern PL, Ward CM. E-cadherin inhibits 
cell surface localization of the pro-migratory 5T4 oncofetal antigen in 
mouse embryonic stem cells. Mol Biol Cell. 2007;18:2838–2851. doi: 
10.1091/mbc.e06-09-0875
 16. Eastham AM, Spencer H, Soncin F, Ritson S, Merry CL, Stern PL, 
Ward CM. Epithelial-mesenchymal transition events during human em-
bryonic stem cell differentiation. Cancer Res. 2007;67:11254–11262. doi: 
10.1158/0008-5472.CAN-07-2253
 17. Torreggiani E, Lisignoli G, Manferdini C, Lambertini E, Penolazzi L, 
Vecchiatini R, Gabusi E, Chieco P, Facchini A, Gambari R, Piva R. Role 
of slug transcription factor in human mesenchymal stem cells. J Cell Mol 
Med. 2012;16:740–751. doi: 10.1111/j.1582-4934.2011.01352.x
 18. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. 
J Clin Invest. 2009;119:1420–1428. doi: 10.1172/JCI39104
 19. Shenoy AK, Jin Y, Luo H, Tang M, Pampo C, Shao R, Siemann DW, Wu L, 
Heldermon CD, Law BK, Chang LJ, Lu J. Epithelial-to-mesenchymal 
transition confers pericyte properties on cancer cells. J Clin Invest. 
2016;126:4174–4186. doi: 10.1172/JCI86623
 20. Lu J, Shenoy AK. Epithelial-to-pericyte transition in cancer. Cancers 
(Basel). 2017;9:E77.
 21. Campagnolo P, Cesselli D, Al Haj Zen A, Beltrami AP, Kränkel N, 
Katare R, Angelini G, Emanueli C, Madeddu P. Human adult vena saphena 




 http://ahajournals.org by on M
arch 20, 2020
1124  Arterioscler Thromb Vasc Biol  June 2019
proangiogenic potential. Circulation. 2010;121:1735–1745. doi: 
10.1161/CIRCULATIONAHA.109.899252
 22. Gubernator M, Slater SC, Spencer HL, et al. Epigenetic profile of 
human adventitial progenitor cells correlates with therapeutic outcomes 
in a mouse model of limb ischemia. Arterioscler Thromb Vasc Biol. 
2015;35:675–688. doi: 10.1161/ATVBAHA.114.304989
 23. Katare R, Riu F, Mitchell K, Gubernator M, Campagnolo P, Cui Y, 
Fortunato O, Avolio E, Cesselli D, Beltrami AP, Angelini G, Emanueli C, 
Madeddu P. Transplantation of human pericyte progenitor cells improves 
the repair of infarcted heart through activation of an angiogenic pro-
gram involving micro-RNA-132. Circ Res. 2011;109:894–906. doi: 
10.1161/CIRCRESAHA.111.251546
 24. Caporali A, Meloni M, Miller AM, et al. Soluble ST2 is regulated by p75 
neurotrophin receptor and predicts mortality in diabetic patients with crit-
ical limb ischemia. Arterioscler Thromb Vasc Biol. 2012;32:e149–e160. 
doi: 10.1161/ATVBAHA.112.300497
 25. Nadgir SV, Hensler HR, Knowlton ER, Rinaldo CR, Rappocciolo G, 
Jenkins FJ. Fifty percent tissue culture infective dose assay for determining 
the titer of infectious human herpesvirus 8. J Clin Microbiol. 2013;51:1931–
1934. doi: 10.1128/JCM.00761-13
 26. Bhattacharya S, Michels CL, Leung MK, Arany ZP, Kung AL, 
Livingston DM. Functional role of p35srj, a novel p300/CBP binding pro-
tein, during transactivation by HIF-1. Genes Dev. 1999;13:64–75.
 27. Elsby LM, O’Donnell AJ, Green LM, Sharrocks AD, Roberts SG. Assembly 
of transcription factor IIB at a promoter in vivo requires contact with RNA 
polymerase II. EMBO Rep. 2006;7:898–903. doi: 10.1038/sj.embor.7400767
 28. Yu B, Wong MM, Potter CM, Simpson RM, Karamariti E, Zhang Z, 
Zeng L, Warren D, Hu Y, Wang W, Xu Q. Vascular stem/progenitor cell 
migration induced by smooth muscle cell-derived chemokine (C-C Motif) 
ligand 2 and chemokine (C-X-C motif) ligand 1 contributes to neointima 
formation. Stem Cells. 2016;34:2368–2380. doi: 10.1002/stem.2410
 29. Mehrad B, Keane MP, Strieter RM. Chemokines as mediators of angio-
genesis. Thromb Haemost. 2007;97:755–762.
 30. Wang L, Wang Z, Yang B, Yang Q, Wang L, Sun Y. CXCR4 nuclear locali-
zation follows binding of its ligand SDF-1 and occurs in metastatic but not 
primary renal cell carcinoma. Oncol Rep. 2009;22:1333–1339.
 31. Braganca J, Swingler T, Marques FIR, Jones T, Eloranta JJ, Hurst HC, 
Shioda T, Bhattacharya S. Human CREB-binding protein/p300-inter-
acting transactivator with ED-rich tail (CITED) 4, a new member of the 
CITED family, functions as a co-activator for transcription factor AP-2. J 
Biol Chem. 2002;277:8559–8565.
 32. Avolio E, Meloni M, Spencer HL, et al. Combined intramyocardial delivery 
of human pericytes and cardiac stem cells additively improves the healing of 
mouse infarcted hearts through stimulation of vascular and muscular repair. 
Circ Res. 2015;116:e81–e94. doi: 10.1161/CIRCRESAHA.115.306146
 33. Chen CW, Corselli M, Péault B, Huard J. Human blood-vessel-derived 
stem cells for tissue repair and regeneration. J Biomed Biotechnol. 
2012;2012:597439. doi: 10.1155/2012/597439
 34. Stern PL, Brazzatti J, Sawan S, McGinn OJ. Understanding and exploiting 
5T4 oncofoetal glycoprotein expression. Semin Cancer Biol. 2014;29:13–
20. doi: 10.1016/j.semcancer.2014.07.004
 35. Moreau JL, Artap ST, Shi H, Chapman G, Leone G, Sparrow DB, 
Dunwoodie SL. Cited2 is required in trophoblasts for correct placental capillary 
patterning. Dev Biol. 2014;392:62–79. doi: 10.1016/j.ydbio.2014.04.023
 36. Freedman SJ, Sun ZY, Kung AL, France DS, Wagner G, Eck MJ. 
Structural basis for negative regulation of hypoxia-inducible factor-1alpha 
by CITED2. Nat Struct Biol. 2003;10:504–512. doi: 10.1038/nsb936
 37. Yin Z, Haynie J, Yang XM, Han BG, Kiatchoosakun S, Restivo J, 
Yuan SY, Prabhakar NR, Herrup K, Conlon RA, Hoit BD, Watanabe M, 
Yang YC. The essential role of Cited2, a negative regulator for HIF-1 
alpha, in heart development and neurulation. Proc Natl Acad Sci USA. 
2002;99:10488–10493.
 38. Yoon H, Lim JH, Cho CH, Huang LE, Park JW. CITED2 controls the 
hypoxic signaling by snatching p300 from the two distinct activation 
domains of HIF-1α. Biochim Biophys Acta. 2011;1813:2008–2016. doi: 
10.1016/j.bbamcr.2011.08.018
 39. Tien ES, Davis JW, Vanden Heuvel JP. Identification of the CREB-binding 
protein/p300-interacting protein CITED2 as a peroxisome proliferator-
activated receptor alpha coregulator. J Biol Chem. 2004;279:24053–
24063. doi: 10.1074/jbc.M401489200
 40. Chou YT, Hsieh CH, Chiou SH, Hsu CF, Kao YR, Lee CC, Chung CH, 
Wang YH, Hsu HS, Pang ST, Shieh YS, Wu CW. CITED2 functions as a 
molecular switch of cytokine-induced proliferation and quiescence. Cell 
Death Differ. 2012;19:2015–2028. doi: 10.1038/cdd.2012.91
 41. Zhang L, Huang G, Li XW, Zhang YJ, Jiang Y, Shen JJ, Liu J, Wang QL, 
Zhu J, Feng XB, Dong JH, Qian C. Hypoxia induces epithelial-mesenchy-
mal transition via activation of SNAI1 by hypoxia-inducible factor-1 alpha 
in hepatocellular carcinoma. BMC Cancer. 2013;13:108.
 42. MacDonald ST, Bamforth SD, Bragança J, Chen CM, Broadbent C, 
Schneider JE, Schwartz RJ, Bhattacharya S. A cell-autonomous role of 
Cited2 in controlling myocardial and coronary vascular development. Eur 
Heart J. 2013;34:2557–2565. doi: 10.1093/eurheartj/ehs056
 43. Li Q, Pan H, Guan L, Su D, Ma X. CITED2 mutation links congenital 
heart defects to dysregulation of the cardiac gene VEGF and PITX2C 
expression. Biochem Biophys Res Commun. 2012;423:895–899. doi: 
10.1016/j.bbrc.2012.06.099
 44. Lopes Floro K, Artap ST, Preis JI, Fatkin D, Chapman G, Furtado MB, 
Harvey RP, Hamada H, Sparrow DB, Dunwoodie SL. Loss of Cited2 
causes congenital heart disease by perturbing left-right patterning of 
the body axis. Hum Mol Genet. 2011;20:1097–1110. doi: 10.1093/ 
hmg/ddq554
 45. Liu Y, Wang F, Wu Y, Tan S, Wen Q, Wang J, Zhu X, Wang X, Li C, 
Ma X, Pan H. Variations of CITED2 are associated with congenital heart 
disease (CHD) in Chinese population. PLoS One. 2014;9:e98157. doi: 
10.1371/journal.pone.0098157
 46. Xu M, Wu X, Li Y, Yang X, Hu J, Zheng M, Tian J. CITED2 mutation 
and methylation in children with congenital heart disease. J Biomed Sci. 
2014;21:7. doi: 10.1186/1423-0127-21-7
 47. Guerra M, Blázquez JL, Rodríguez EM. Blood-brain barrier and foe-
tal-onset hydrocephalus, with a view on potential novel treatments 
beyond managing CSF flow. Fluids Barriers CNS. 2017;14:19. doi: 
10.1186/s12987-017-0067-0
 48. Katare R, Stroemer P, Hicks C, Stevanato L, Patel S, Corteling R, 
Miljan E, Vishnubhatla I, Sinden J, Madeddu P. Clinical-grade human 
neural stem cells promote reparative neovascularization in mouse models 
of hindlimb ischemia. Arterioscler Thromb Vasc Biol. 2014;34:408–418. 
doi: 10.1161/ATVBAHA.113.302592
 49. Lan F, Liu J, Narsinh KH, Hu S, Han L, Lee AS, Karow M, Nguyen PK, Nag D, 
Calos MP, Robbins RC, Wu JC. Safe genetic modification of cardiac stem 
cells using a site-specific integration technique. Circulation. 2012;126(11 
suppl 1):S20–S28. doi: 10.1161/CIRCULATIONAHA.111.084913
 50. Nowakowski A, Walczak P, Lukomska B, Janowski M. Genetic engi-
neering of mesenchymal stem cells to induce their migration and survival. 
Stem Cells Int. 2016;2016:4956063. doi: 10.1155/2016/4956063
 51. Vågesjö E, Öhnstedt E, Mortier A, Lofton H, Huss F, Proost P, Roos S, 
Phillipson M. Accelerated wound healing in mice by on-site production 
and delivery of CXCL12 by transformed lactic acid bacteria. Proc Natl 
Acad Sci USA. 2018;115:1895–1900. doi: 10.1073/pnas.1716580115
Highlights
• TPBG (trophoblast glycoprotein) is abundantly expressed in human pericytes following exposure to hypoxia or ischemia and this is associated 
with upregulation and secretion of CXCL12 (chemokine [C-X-C motif] ligand-12)/CXCR7 (C-X-C chemokine receptor type 7) and pERK, resulting 
in activation of migration and angiogenesis.
• CITED2 (Atypical chemokine receptor 3 CBP/p300-interacting transactivator with glutamic acid (E)/aspartic acid (D)-rich tail) acts as a tran-
scriptional regulator of TPBG, especially under hypoxic conditioning.
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